APA (7th ed.) Citation

Pandey​, K., Pal, B., Siddiqui, N. A., Lal, C. S., Ali, V., Bimal, S., . . . Das, V. N. R. (2021). A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis. Indian Journal of Dermatology, Venereology & Leprology, 87(1), 34. https://doi.org/10.25259/IJDVL_410_19

Chicago Style (17th ed.) Citation

Pandey​, Krishna, et al. "A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Liposomal Amphotericin B (AmBisome) Versus Miltefosine in Patients with Post-kala-azar Dermal Leishmaniasis." Indian Journal of Dermatology, Venereology & Leprology 87, no. 1 (2021): 34. https://doi.org/10.25259/IJDVL_410_19.

MLA (9th ed.) Citation

Pandey​, Krishna, et al. "A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Liposomal Amphotericin B (AmBisome) Versus Miltefosine in Patients with Post-kala-azar Dermal Leishmaniasis." Indian Journal of Dermatology, Venereology & Leprology, vol. 87, no. 1, 2021, p. 34, https://doi.org/10.25259/IJDVL_410_19.